SAILIFE · NSE
Sai Life Sciences Limited
₹1,600.5
+3.55% (+₹54.8)
Prev. close
₹1,545.7
Volume
8,67,960
Delivery %
58.0%
As of
18 Sept 2026
Price history
Vaishali Parekh · Prabhudas Lilladher · 26 Aug 2026
“Bullish on Sai Life Sciences, recommending a buy at ₹1440 with a target of ₹1480 and a stop loss at ₹1420 for today's trading session.”
Entry ₹1,440Target ₹1,480 (+2.8%)Stop ₹1,420 (-1.4%)R:R 2.0:1Target hit · 27 Aug 2026
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Bullish on Sai Life Sciences, recommending a buy at ₹1440 with a target of ₹1480 and a stop loss at ₹1420 for today's tr…” | Vaishali ParekhPrabhudas Lilladher | Sai Life Sciences | PENDING | ||||
“Bullish on Sai Life Sciences, recommending a buy at ₹1440 with a target of ₹1480 and a stop loss at ₹1420 for today's trading session.” This call hasn't reached its evaluation window yet — the verdict will appear here once it's graded. | |||||||
Fundamentals
About Sai Life Sciences Limited
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It offers medicinal chemistry, pharmacokinetics, clinical and commercial manufacturing, and process development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Krishnam Raju Kanumuri
Headquarters
Hyderabad
Employees
5,224
Website
sailife.comExchange
View on NSE ↗Key stats
Market cap
₹33,993.69 Cr
P/E ratio (TTM)
94.1
EPS (TTM)
₹17.00
Beta (1Y · daily vs NIFTY 50)
0.80
Shares float
12.58 Cr
EPS · quarter ended Jun 2026
₹3.42
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹1,196.95 Cr | ₹1,456.47 Cr | ₹1,660.39 Cr | ₹2,192.49 Cr | |
| EBITDA | ₹192.90 Cr | ₹314.58 Cr | ₹442.44 Cr | ₹672.29 Cr |
| ₹9.99 Cr | ₹82.81 Cr | ₹170.13 Cr | ₹348.91 Cr | |
| Diluted EPS | ₹0.48 | ₹3.98 | ₹8.61 | ₹16.43 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹2,186.65 Cr | ₹2,275.14 Cr | ₹3,159.98 Cr | ₹3,626.14 Cr | |
| ₹932.38 Cr | ₹927.66 Cr | ₹352.38 Cr | ₹288.45 Cr | |
| Stockholders' equity | ₹888.09 Cr | ₹975.14 Cr | ₹2,128.36 Cr | ₹2,483.69 Cr |
CWIP, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹219.40 Cr | ₹263.09 Cr | ₹314.05 Cr | ₹509.13 Cr | |
| Investing cash flow | ₹-101.78 Cr | ₹-192.38 Cr | ₹-536.67 Cr | ₹-395.41 Cr |
| ₹-200.65 Cr | ₹-95.30 Cr | ₹301.43 Cr | ₹-123.68 Cr | |
| Capital expenditure | ₹-113.08 Cr | ₹-181.69 Cr | ₹-369.28 Cr | ₹-592.96 Cr |
| End cash position | ₹35.53 Cr | ₹11.97 Cr | ₹91.05 Cr | ₹81.91 Cr |
Dividends paid has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|
| Promoter | 35.24% | 35.17% | 35.15% | 34.94% | 34.70% | 34.61% | 34.53% |
| Public | 64.76% | 64.83% | 64.85% | 65.06% | 65.30% | 65.39% | 65.47% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Sai Life Sciences Limited | ₹32,677.19 Cr | ₹1,545.7 | 90.7 | 13.16 | 14.0% | 0.12 | +28.7% | +72.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
29 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Sai Life Sciences (SAILIFE.NS) Slips Over 5% as Stock Retreats Toward Key Support - Long Short Pair
siam.in · 8 days ago
SAI LIFE SCIENCES Share Price Today: Down 2.72%
SAI LIFE SCIENCES shares fell 2.72% to Rs 1,629.65, with the company's market capitalization at Rs 34,967.52 crore. The decline occurred without a specific company-identified catalyst. The stock trades at elevated valuation ratios but also shows above-industry profitability metrics.